User: Guest  Login
Title:

Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.

Document type:
Clinical Trial; Clinical Trial, Phase II; Journal Article
Author(s):
Eckel, F; Schmelz, R; Erdmann, J; Mayr, M; Lersch, C
Abstract:
The antitumor effect of gemcitabine is not dose-response related but schedule dependent. Here we report a phase II trial of a weekly 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic cancer. Patients with histologically proven, measurable, and irresectable pancreatic adenocarcinoma were treated with gemcitabine at a dose of 100 mg/m2 infused over 24 hr on days 1, 8, and 15. Treatment was repeated every 28 days until progression of disease or limiting toxic...     »
Journal title abbreviation:
Cancer Invest
Year:
2003
Journal volume:
21
Journal issue:
5
Pages contribution:
690-4
Language:
eng
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/14628426
Print-ISSN:
0735-7907
TUM Institution:
II. Medizinische Klinik und Poliklinik (Gastroenterologie)
 BibTeX